BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11116133)

  • 1. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
    Burrell LM; Farina NK; Balding LC; Johnston CI
    Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
    Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
    Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
    J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
    Helin K
    Scand J Clin Lab Invest; 1993 Dec; 53(8):843-51. PubMed ID: 8140395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
    Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W; Beslot F; Laboulandine I; FourniƩ-Zaluski MC; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
    Naitoh M; Risvanis J; Balding LC; Johnston CI; Burrell LM
    Cardiovasc Res; 2002 Apr; 54(1):51-7. PubMed ID: 12062361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    J Pharmacol Exp Ther; 2003 Apr; 305(1):97-105. PubMed ID: 12649357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
    Hubner RA; Kubota E; Casley DJ; Johnston CI; Burrell LM
    J Hypertens; 2001 May; 19(5):941-6. PubMed ID: 11393678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.